Overview

CX717 in the Treatment of Adult ADHD

Status:
Completed

Trial end date:
2006-01-10

Target enrollment:

Participant gender:

Summary

A Randomized, Double-Blind, Two-Period Crossover Study to Assess the Efficacy And Safety of the Ampakine® Compound, CX717, versus Placebo in Adults with Attention-Deficit Hyperactivity Disorder

Phase:

Phase 2

Details

Lead Sponsor:

RespireRx